Literature DB >> 10863109

Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.

R N Jones1, D J Biedenbach, D M Johnson.   

Abstract

Cefditoren (formerly ME-1206) is an investigational, orally administered cephalosporin ester with bactericidal activity against many Gram-positive and -negative organisms. Cefditoren potency against nearly 1000 non-fastidious species was determined by National Committee for Clinical Laboratory Standards (NCCLS) reference broth microdilution and standardized disk diffusion methods. Against staphylococci, usable cefditoren activity was completely correlated with oxacillin with respect to potency and susceptibility interpretation (mec A-negative strains). Cefditoren was very active against Klebsiella spp., Proteus mirabilis, Salmonella spp., and Escherichia coli (MIC(90) range, 0.12-1 microg/ml; median zone, 23-26 mm). Cefditoren had more limited activity against Citrobacter spp., Enterobacter spp., Serratia marcescens, and indole-positive Proteae (MIC(50) range, 0.12-1 microg/ml; MIC(90), > 16 microg/ml; median zone, 18-25 mm). Against Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter spp., and other non-fermentors, cefditoren was inactive (MIC(90), > 16 microg/ml; zone, 6 mm). Pharmacokinetic analysis of cefditoren showed that utilized dosages produce a plasma concentration that exceeds 0.5 microg/ml for 5 to 8 h and 1 microg/ml for 4 to 6 hours (T(1/2) ranges from 1.5-2 h). The following interpretive criteria were suggested: </= 2 microg/ml or >/= 15 mm (susceptible) and >/= 8 microg/ml or </= 11 mm (resistance) that yielded an intermethod categorical agreement of 95.8% and very major or major error rates of 0.7% and 0.3%, respectively. Alternatively, </= 1 microg/ml or >/= 18 mm (susceptible) and >/= 4 microg/ml or </= 14 mm (resistant) breakpoints resulted in 96.2% accuracy and combined serious errors of only 1.1%. Cefditoren was observed to be a very active cephalosporin ranking among the most potent available orally active beta-lactams for use against a wide variety of pathogens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10863109     DOI: 10.1016/s0732-8893(00)00135-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.

Authors:  David Sevillano; Lorenzo Aguilar; Luis Alou; María-José Giménez; Martha Torrico; Natalia González; Fabio Cafini; María-Teresa Relaño; Pilar Coronel; José Prieto
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

2.  Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.

Authors:  Thomas P Lodise; Martina Kinzig-Schippers; George L Drusano; Ulrich Loos; Friedrich Vogel; Jürgen Bulitta; Markus Hinder; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

Review 3.  Cefditoren pivoxil.

Authors:  Malcolm J M Darkes; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 11.431

4.  Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients.

Authors:  Despina Hatzaki; Garyphallia Poulakou; Ioannis Katsarolis; Niki Lambri; Maria Souli; Ioannis Deliolanis; Georgios K Nikolopoulos; Evangelia Lebessi; Helen Giamarellou
Journal:  BMC Infect Dis       Date:  2012-09-25       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.